U085 Immune (Dys)regulation in Autoimmune Skin Diseases
DESCRIPTION
Autoimmune diseases show an imbalance in immune activation and immune regulation by impaired regulatory T (Treg) cells. This session will teach a) the basic principles of immune regulation during homeostasis, b) identify mechanisms of immune dysregulation and autoimmunity, including sex and race differences, and ultimately c) novel strategies how to treat immune dysregulation by Treg cell-inducing approaches in vivo (interleukin-2, mTOR-inhibitors, dietary/microbiome-based) and ex vivo (polyclonal, clonal antigen-specific and engineered ag-specific (CAR, CAAR, BAR) Treg cell expansion), and d) presenting data from clinical trials using these approaches to induce immune tolerance.
LEARNING OBJECTIVES
Discuss the basic principles of immune regulation during homeostasis.
Identify mechanisms of immune dysregulation in autoimmune skin diseases.
Demonstrate novel strategies how to induce immune tolerance as a treatment for immune dysregulation.
DIRECTOR
Antonios G.A. Kolios, MD, IFAAD
CO-DIRECTOR
Johann E. Gudjonsson, MD, FAAD
SPEAKERS
Aaron Mangold, MD, FAAD
Matthew Vesely, MD, PhD, FAAD
DISCLOSURES
Johann E. Gudjonsson, MD, FAAD
AbbVie – Investigator(Grants/Research Funding); Eli Lilly – Advisory Board(Honoraria); Galderma – Advisory Board(Honoraria), Other(Grants/Research Funding); Genentech, Inc. – Investigator(Grants/Research Funding); Janssen Pharmaceuticals, Inc – Advisory Board(Honoraria); miRagen Therapeutics, Inc. – Consultant(Honoraria); Novartis – Advisory Board(Fees), Advisory Board(Honoraria), Other(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Investigator(Grants/Research Funding); Zura Bio – Advisory Board(Honoraria);
Antonios G.A. Kolios, MD, IFAAD
No financial relationships exist with ineligible companies.
Aaron Mangold, MD, FAAD
arGEN-X – Investigator(Grants/Research Funding); Astra Zeneca – Investigator(Grants/Research Funding); Atlas Med – Other(Patent royalties or other compensation for Intellectual Property Rights); Boehringer Ingelheim – Consultant(Honoraria); Bristol Myers Squibb – Investigator(Grants/Research Funding); clarivate – Consultant(Grants/Research Funding); Dragonfly Therapeutics – Consultant (1099 relationship)(Honoraria); Eli Lilly and Company – Investigator(Grants/Research Funding); EMD Serono – Investigator(Grants/Research Funding); Incyte Corporation – Investigator(Grants/Research Funding); Insmed – Investigator(Grants/Research Funding); Janssen Global Services, LLC – Consultant(Honoraria); Kyowa Kirin – Investigator(Grants/Research Funding); Merck – Investigator(Grants/Research Funding); miRagen Therapeutics, Inc. – Investigator(Grants/Research Funding); Novartis – Investigator(Grants/Research Funding); Pfizer Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Priovant – Investigator(Grants/Research Funding); Priovant Therapeutics – Other(Patent royalties or other compensation for Intellectual Property Rights); Regeneron Pharmaceuticals, Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Scitech Development – Investigator(Grants/Research Funding); Solgenix, Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding);
Matthew Vesely, MD, PhD, FAAD
Priovant Therapeutics – Consultant (1099 relationship)(Fees); Regeneron – Employee(Salary); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Fees);